Pliant Therapeutics paused its phase 2b/3 trial of bexotegrast for idiopathic pulmonary fibrosis due to DSMB recommendations.

If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

Shares in Amazon ( AMZN) are up nearly 46% over the past year, with the stock hitting a record high closing price of $238.15 ...

(RTTNews) - The U.S. Food and Drug Administration has approved AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) ENHERTU (fam-trastuzumab deruxtecan-nxki) for the treatment of adult ...

The FDA has approved AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab ... The average risk of a woman getting breast cancer during her lifetime is 13%. Currently, it is the second leading cause ...

WASHINGTON: The Central Intelligence Agency on Saturday shifted its official stance on the origin of COVID-19, saying that it ...

AstraZeneca (NASDAQ:AZN ... and label expansions for Tagrisso and Imfinzi in the second half of the previous year. It is equally critical to discuss the successes and failures in the ...

MANILA, Philippines — Civilian government workers are set to receive the second tranche of their salary increase this January after Budget Secretary Amenah Pangandaman signed the circular ...

the Rotunda of the U.S. Capitol on January 20, 2025 in Washington, DC. Donald Trump takes office for his second term as the 47th president of the United States. (Photo by Chip Somodevilla/Getty ...

Bookings are currently open and deliveries are expected to commence from mid-February. Syros HTK (O) 2nd base model full details, walkaround Ahead of Syros launch, dispatches to dealerships have ...

The Securities and Exchange Commission is rolling out a new cryptocurrency task force, the first big move in the crypto space of Donald Trump's second term in the White House. The SEC announced ...